Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus

American Journal of Physiology - Renal Physiology

Volumn 308, Issue 2, 2015, Pages F77-F83

  Lytvyn, Yuliya ^a,b   Škrtić, Marko ^a   Yang, Gary K ^a   Yip, Paul M ^c   Perkins, Bruce A ^d   Cherney, David Z I ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Hyperglycemia; Uricosuria

Indexed keywords

ALDOSTERONE; EMPAGLIFLOZIN; GLUCOSE; SODIUM; SODIUM GLUCOSE COTRANSPORTER 2; URIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE URINE LEVEL; GLUCOSURIA; HEART RATE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY PLASMA FLOW; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; URIC ACID URINE LEVEL; URINARY EXCRETION; ELEVATED BLOOD PRESSURE; SYSTOLIC BLOOD PRESSURE;

EID: 84928634207     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00555.2014     Document Type: Article

References (41)

1. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, Srivastava S, Kitamura K, Hisatome I, Endou H, Sakurai H. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 283: 26834–26838, 2008.
2. Augustin R, Carayannopoulos MO, Dowd LO, Phay JE, Moley JF, Moley KH. Identification and characterization of human glucose transporter- like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem 279: 16229–16236, 2004.
3. Bahn A, Hagos Y, Reuter S, Balen D, Brzica H, Krick W, Burckhardt BC, Sabolic I, Burckhardt G. Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). J Biol Chem 283: 16332–16341, 2008.
4. Bonsnes RW, Dana ES. On the increased uric acid clearance following the intravenous infusion of hypertonic glucose solutions. J Clin Invest 25: 386–388, 1946.
5. Cherney DZ, Miller JA, Scholey JW, Bradley TJ, Slorach C, Curtis JR, Dekker MG, Nasrallah R, Hebert RL, Sochett EB. The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes 57: 688–695, 2008.
6. Cherney DZ, Perkins BA. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection? Can J Diabetes 38: 356–363, 2014.
7. Cherney DZ, Reich HN, Miller JA, Lai V, Zinman B, Dekker MG, Bradley TJ, Scholey JW, Sochett EB. Age is a determinant of acute hemodynamic responses to hyperglycemia and angiotensin II in humans with uncomplicated type 1 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol 299: R206–R214, 2010.
8. Cherney DZI, Miller JA, Scholey JW, Bradley TJ, Slorach C, Curtis JR, Dekker MG, Nasrallah R, Hébert RL, Sochett EB. The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes 57: 688–695, 2008.
9. Cherney DZI, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129: 587–597, 2014.
10. Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi JI, Nakanishi T, Tamai I. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dis 35: 391–404, 2014.
11. Choi HK, Ford ES. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels–the Third National Health and Nutrition Examination Survey. Rheumatology 47: 713–717, 2008.
12. Erdogan D, Gullu H, Caliskan M, Yildirim E, Bilgi M, Ulus T, Sezgin N, Muderrisoglu H. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract 59: 1276–1282, 2005.
13. Feig DI, Rodriguez-Iturbe B, Nakagawa T, Johnson RJ. Nephron number, uric acid, and renal microvascular disease in the pathogenesis of essential hypertension. Hypertension 48: 25–26, 2006.
14. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obesity Metab 15: 721–728, 2013.
15. Ficociello LH, Rosolowsky ET, Niewczas MA, Maselli NJ, Weinberg JM, Aschengrau A, Eckfeldt JH, Stanton RC, Galecki AT, Doria A, Warram JH, Krolewski AS. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 33: 1337–1343, 2010.
16. Florijn KW, Barendregt JN, Lentjes EG, van Dam W, Prodjosudjadi W, van Saase JL, van Es LA, Chang PC. Glomerular filtration rate measurement by “single-shot” injection of inulin. Kidney Int 46: 252–259, 1994.
17. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, Arroyo D, Luno J. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5: 1388–1393, 2010.
18. Gonzalez-Sicilia L, Garcia-Estan J, Martinez-Blazquez A, Fernandez- Pardo J, Quiles JL, Hernandez J. Renal metabolism of uric acid in type I insulin-dependent diabetic patients: relation to metabolic compensation. Horm Metab Res 29: 520–523, 1997.
19. Gordin D, Ronnback M, Forsblom C, Makinen V, Saraheimo M, Groop PH. Glucose variability, blood pressure and arterial stiffness in type 1 diabetes. Diabetes Res Clin Pract 80: e4–e7, 2008.
20. Gotfredsen A, McNair P, Christiansen C, Transbol I. Renal hypouricaemia in insulin treated diabetes mellitus. Clin Chim Acta 120: 355–361, 1982.
21. Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 18: 430–439, 2007.
22. Herman JB, Goldbourt U. Uric acid and diabetes: observations in a population study. Lancet 2: 240–243, 1982.
23. Jalal DI, Rivard CJ, Johnson RJ, Maahs DM, McFann K, Rewers M, Snell-Bergeon JK. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dialysis Transplan 25: 1865–1869, 2010.
24. Jones SL, Kontessis P, Wiseman M, Dodds R, Bognetti E, Pinto J, Viberti G. Protein intake and blood glucose as modulators of GFR in hyperfiltering diabetic patients. Kid Int 41: 1620–1628, 1992.
25. Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I, Duranay M, Covic A, Johnson RJ. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 6: 1887–1894, 2011.
26. Kanbay M, Yilmaz MI, Sonmez A, Turgut F, Saglam M, Cakir E, Yenicesu M, Covic A, Jalal D, Johnson RJ. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol 33: 298–304, 2011.
27. Kimura T, Takahashi M, Yan K, Sakurai H. Expression of SLC2A9 isoforms in the kidney and their localization in polarized epithelial cells. PloS one 9: e84996, 2014.
28. Lewis G, Maxwell AP. Risk factor control is key in diabetic nephropathy. Practitioner 258: 13–17, 2014.
29. Lytvyn Y, Perkins BA, Cherney DZI. Uric acid as a biomarker and a therapeutic target in diabetes. Can J Diabetes In Press.
30. Maahs DM, Caramori L, Cherney DZ, Galecki AT, Gao C, Jalal D, Perkins BA, Pop-Busui R, Rossing P, Mauer M, Doria A. Uric acid lowering to prevent kidney function loss in diabetes: the Preventing Early Renal Function Loss (PERL) Allopurinol Study. Curr Diabetes Rep 13: 550–559, 2013.
31. Miller JA. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 10: 1778–1785, 1999.
32. Momeni A, Shahidi S, Seirafian S, Taheri S, Kheiri S. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis 4: 128–132, 2010.
33. Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E. Effect of insulin on uric acid excretion in humans. Am J Physiol Endocrinol Metab 268: E1–E5, 1995.
34. Rodriguez G, Soriano LC, Choi HK. Impact of diabetes against the future risk of developing gout. Ann Rheum Dis 69: 2090–2094, 2010.
35. Rosolowsky ET, Ficociello LH, Maselli NJ, Niewczas MA, Binns AL, Roshan B, Warram JH, Krolewski AS. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 3: 706–713, 2008.
36. Skeith MD, Healey LA, Cutler RE. Effect of phloridzin on uric acid excretion in man. Am J Physiol 219: 1080–1082, 1970.
37. Wang C, Pan Y, Zhang QY, Wang FM, Kong LD. Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. PloS one 7: e38285, 2012.
38. Weir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin 30: 1759–1768, 2014.
39. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol 17: 7–13, 2011.
40. Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obesity Metab 15: 403–409, 2013.
41. Yang GK, Maahs DM, Perkins B, Cherney DZI. Renal hyperfiltration and systemic blood pressure in patients with uncomplicated type 1 diabetes mellitus. PloS one 8: e68908, 2013.